Aim: Prior randomized controlled trials of acute respiratory distress syndrome (ARDS) excluded critically ill patients with cirrhosis. Data regarding risk factors for ARDS development and outcomes from ARDS in patients with cirrhosis are scarce. We sought to characterize outcomes from ARDS in patients with cirrhosis.
INTRODUCTION
A CUTE RESPIRATORY DISTRESS syndrome (ARDS) is a severe form of non-cardiogenic pulmonary edema and hypoxic respiratory failure identified in patients who meet the Berlin definition. 1 The Berlin definition is comprised of several parameters, including respiratory failure that is not fully explained by hydrostatic pulmonary edema, onset within 1 week of a predisposing condition, bilateral opacities on chest imaging, and a partial pressure of arterial blood-to-fraction of inspired oxygen (PaO2/ FiO2) ratio <300 mmHg. 1 Incidence rates for ARDS are approximately 10.4% among all intensive care unit (ICU) admissions, with hospital mortality between 35% and 46%. 2 Major efforts are currently underway to identify at-risk patients with a more focused approach on many subphenotypes of ARDS. 3 However, data regarding ARDS in patients with cirrhosis are limited despite increasing survivorship of these patients. 4, 5 This is in part due to prior randomized clinical trials from the National Heart, Lung, Blood Institute's ARDS Network excluding patients with severe liver disease or cirrhosis. 6, 7 More studies on ARDS in patients with liver cirrhosis are required to inform the management of this complex cohort of patients.
Many predisposing conditions contribute to the development of ARDS, with the most common being sepsis, but also including pneumonia, aspiration, multiple transfusions, and pancreatitis. [8] [9] [10] Risk modifiers including alcohol use disorder and tobacco use also contribute to the risk for ARDS development. 9, 11, 12 Alcohol use disorder is one of the most common etiologies for cirrhosis development, 13 as well as a risk modifier for ARDS development in the Lung Injury Prediction Score. 9, 14 Patients with decompensated cirrhosis have a dysregulated innate immune response with elevated levels of the pro-inflammatory cytokines, interleukin-6 and interleukin-8, 15 that contribute to severe lung injury in those at-risk. 16 , 17 The handful of predisposing conditions and risk modifiers in ARDS are common in patients with cirrhosis, and are further complicated by baseline immune dysfunction and additional respiratory complications from pulmonary edema and pleural effusions. 18 This predisposition to respiratory failure can contribute to acute-on-chronic liver failure (ACLF), where requirement for mechanical ventilation has been shown to be a poor prognostic indicator. 19, 20 These factors contribute to a complex phenotype with little information regarding risk factors and outcomes unique to patients with cirrhosis and ARDS.
We aimed to examine the predisposing conditions and risk modifiers for development of ARDS that are important in patients with cirrhosis, and to investigate the outcomes after development of ARDS in this phenotype. We hypothesized that sepsis is the predisposing condition and alcohol use is the risk modifier of most importance. We also hypothesized that the in-hospital mortality is high in patients with decompensated cirrhosis who develop ARDS compared with their counterparts without ARDS.
METHODS

Patient selection and environment
A N OBSERVATIONAL COHORT of consecutive patients with cirrhosis who were admitted to an ICU at Loyola University Medical Center (Maywood, IL, USA) between 1 January 2012 and 31 December 2014 were reviewed retrospectively. Loyola University Medical Center is a large, academic tertiary care medical center with a highvolume liver transplant program. Eligibility criteria included the following: aged ≥16 years, clinical diagnosis of cirrhosis, and admission to an ICU. Cases of cirrhosis were determined by two prior encounters with diagnosis of cirrhosis, and the diagnosis was confirmed via chart review by two physicians (P. Y., P. F.). For patients who had multiple recorded admissions that met the eligibility criteria, only the most recent admission was included for analysis.
ARDS case identification
Two blinded physician reviewers (P. Y., P. F.) independently reviewed the electronic medical record following the Berlin definition for ARDS. 1 The two physician reviewers had experience and underwent further training in applying the Berlin definition by a pulmonary and critical care physician with expertise in ARDS research (M. A.). In the cases of discordant patient assessment between the two physician reviewers, adjudication was carried out by a third expert reviewer (M. A.). Substantial interobserver reliability between the two reviewers was observed, with κ-coefficient 0.66 (95% confidence interval [CI] 0.56-0.78). Adjudication was carried out in 28 patients. Common reasons for discordance included differing classification of pulmonary edema between reviewers, and not meeting the 1-week time criteria for the Berlin definition of ARDS.
Outcome measurements
The primary outcome was development of ARDS. Secondary outcomes were 28-day ventilator-free days (defined as number of days alive and breathing spontaneously without the aid of a ventilator for at least 48 h in a 28-day period from ICU admission), 21 28-day ICU-free days (defined as number of days alive and outside the ICU in a 28-day period from ICU admission), most recent known transplant status, and in-hospital death.
Candidate variables
Potential risk modifiers and predisposing conditions for development for ARDS were selected a priori, which included age, sex, sepsis, alcohol use disorder, tobacco use, diabetes, 11, 12, 22 presence of shock (cardiovascular component of Sequential Organ Failure Assessment [SOFA] score ≥2, which is requirement for vasoactive agents such as dopamine, dobutamine, epinephrine, or norepinephrine), renal dysfunction (renal component of SOFA score ≥2, which is serum creatinine concentration ≥2.0 mg/dL or urine output <500 mL/day), coagulopathy (coagulation component of SOFA score ≥2, which is platelet count <100 000/μL), 23 etiology of cirrhosis, [15] [16] [17] [18] 24 Charlson Comorbidity Index, 25 Model for EndStage Liver Disease -Sodium (MELD-Na) score, 26 and ACLF (yes or no). 19 Etiology of cirrhosis was abstracted from the electronic medical record by the physician reviewers. For patients who had alcoholism and another etiology of cirrhosis listed concurrently in the chart, only those with alcohol use disorder listed as the sole etiology of cirrhosis were categorized as having alcoholic cirrhosis. For the patients who developed ARDS, the SOFA scores were also compared between the time of admission to ICU and the time of ARDS diagnosis.
Statistical analysis
Baseline characteristics were presented as medians with interquartile ranges and compared using WilcoxonMann-Whitney or Kruskal-Wallis non-parametric tests with continuous variables. A comparison of two or more proportions was carried out using the χ 2 -test. Logistic regression was used to assess the risk for ARDS development.
The candidate variables listed previously were entered into a univariable logistic regression. Candidate variables with P < 0.2 in the univariable analysis were examined in a multivariable logistic regression analysis, 27 and the area under the receiver operating characteristic curve was calculated with the multivariable model. Cirrhosis type as a dichotomous variable for alcoholic cirrhosis (yes or no) and MELD-Na score were forced into the final model, because they were the primary aims of the present study. Infection-related ACLF (yes or no) according to the study on the North American Consortium for the Study of End-Stage Liver Disease database was added into the final model to examine its association with ARDS. 19 ACLF in the North American Consortium for the Study of EndStage Liver Disease database was defined as two or more organ failures among West Haven hepatic encephalopathy grade III or IV, shock (mean arterial pressure <60 mmHg or reduction of 40 mmHg in systolic blood pressure from baseline), need for mechanical ventilation, or need for renal replacement therapy. 19 Hosmer-Lemeshow test was used to assess the goodness-of-fit for the model. Comparisons for the secondary outcomes were also made by ARDS severity.
The institutional review boards of Loyola University Chicago approved this study. Analysis was carried out using SAS Version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Patient selection and baseline characteristics
A TOTAL OF 822 adult patients with cirrhosis were admitted to an ICU during the study period. After selecting the most recent ICU admission, 559 unique patients remained in the analysis cohort. A total of 45 patients (8.1%) met criteria for ARDS. The median time from hospital admission to ARDS development was 2.6 days (interquartile range [IQR] 0.40-4.0). The most common predisposing condition for ARDS was sepsis (84.4%, n = 38), followed by pneumonia (n = 3), aspiration (n = 1), trauma (n = 1), and soft tissue infection (n = 1). A total of 25 ARDS patients had positive cultures, and of these, 16 patients had positive cultures from multiple sources. The most common sources of positive cultures were blood (n = 14), followed by ascites fluid (n = 7) and urine (n = 7). The most commonly identified organisms were Enterococcus faecium or Enterococcus faecalis (n = 7), Pseudomonas aeruginosa (n = 5), Escherichia coli (n = 4), and Klebsiella pneumoniae (n = 4). Notable differences between the ARDS and non-ARDS patients included sepsis diagnosis, MELD-Na score, and multiple organ dysfunctions per SOFA criteria (Table 1 ). There were no differences between the ARDS and non-ARDS patients with regard to the Charlson Comorbidity Index and the etiology of cirrhosis. The proportion of patients with an alcohol use disorder or tobacco use was also not different between the ARDS and non-ARDS patients (Table 1) . Hepatocellular carcinoma (with or without treatment or transplant) was identified in 7% (n = 39) of the cohort, and the case-rate was not different between ARDS and non-ARDS patients (P = 0.93).
In patients who developed ARDS, respiratory, cardiovascular, and central nervous system components of the SOFA scores increased significantly from the time of ICU admission to the time of ARDS diagnosis (P = 0.001, P < 0.001, P = 0.03 for respiratory, cardiovascular, and central nervous system components, respectively; Table 1 ). ACLF was present in a much greater proportion in patients with ARDS than in patients without ARDS (Table 1 ). In patients with ARDS, sepsis was present in all patients with ACLF. At the time of ARDS diagnosis, the proportion with mild, moderate, and severe ARDS cases was 31.1% (n = 14), 42.2% (n = 19), and 26.6% (n = 12), respectively. Nine patients with mild ARDS and 12 patients with moderate ARDS subsequently progressed to a higher severity of ARDS. A total of 30 patients met the criteria for severe ARDS at some point during the admission.
Outcome measurements
The median 28-day ICU-free days was markedly lower in ARDS patients compared with those without ARDS (0 [IQR 0-0] vs. 22 [IQR 0-25], P < 0.001). ARDS patients also had significantly lower 28-day ventilator-free days compared with non-ARDS patients (Table 2 ). In-hospital death occurred in 82.2% of ICU patients with cirrhosis who developed ARDS, compared with 27.6% of patients without ARDS (P < 0.001). The proportion of in-hospital death did not differ between the different severities of ARDS (Table 2) . Of those who died, the proportion of patients who died from an infectious etiology was not different between the ARDS and non-ARDS groups (P = 0.08). In the patients with ARDS, neither an increase in cardiovascular SOFA score (P = 0.48) nor an increase in renal SOFA score (P = 0.13) was associated with in-hospital death. Respiratory (n = 339) 37 method or sepsis + vasopressor use, or sepsis + lactate ≥4 mmol/L. ¶Primary or secondary diagnosis of alcohol cirrhosis or administrative data for alcohol dependence. † †SOFA: For respiratory system, 0 = PaO2/FiO2 ≥400, 1 = PaO2/FiO2 <400, 2 = PaO2/FiO2 <300, 3 = PaO2/FiO2 <200, 4 = PaO2/FiO2 <100. For coagulation, 0 = platelets ≥150 000/μL, 1 = platelets <150 000/μL, 2 = platelets <100 000/μL, 3 = platelets <50 000/μL, 4 = platelets <20 000/μL. For liver, 0 = bilirubin <1.2 mg/dL, 1 = bilirubin 1.2-1.9 mg/dL, 2 = bilirubin 2.0-5.9 mg/dL, 3 = bilirubin 6.0-11.9 mg/dL, 4 = bilirubin >12.0 mg/dL. For cardiovascular, 0 = mean arterial pressure (MAP) ≥70 mmHg, 1 = MAP <70 mmHg, 2 = dopamine <5 μg/kg/min or dobutamine any dose, 3 = dopamine 5.1-15 μg/kg/min or epinephrine/norepinephrine ≤0.1 μg/kg/min, 4 = dopamine >15 μg/kg/min or epinephrine/norepinephrine >0.1 μg/kg/min. For central nervous system, 0 = Glasgow coma scale (GCS) 15, 1 = GCS 13-14, 2 = GCS 10-12, 3 = GCS 6-9, 4 = GCS <6. For renal, 0 = creatinine <1.2 mg/dL, 1 = creatinine 1.2-1.9 mg/dL, 2 = creatinine 2.0-3.4 mg/dL, 3 = creatinine 3.5-4.9 mg/dL or urine output <500 mL/day, 4 = creatinine >5.0 mg/dL or urine output <200 mL/day. MELD-Na, Model for End-Stage Liver Disease -Sodium; N/A, not available.
Predisposing conditions and risk modifiers for ARDS
In the univariable logistic regression analysis of the predisposing conditions and risk modifiers for development of ARDS, increased odds was noted from sepsis (OR 9.77, 95% CI 4.06-23.48, P < 0.001), the presence of shock on admission (OR 5.36, 95% CI 2.84-10.13, P < 0.001), and renal dysfunction (OR 2.28, 95% CI 1.23-4.21, P = 0.009). Neither alcohol use disorder (OR 0.99, 95% CI 0.53-1.83, P = 0.99) nor alcohol cirrhosis (OR 1.63, 95% CI 0.62-4.29, P = 0.985) was associated with ARDS development. In the multivariable analysis adjusted for sex, diabetes, sepsis, cirrhosis type, ACLF, cardiovascular dysfunction, renal dysfunction, and MELD-Na score, ACLF had an OR of 8.69 (95% CI 2.28-33.18, P < 0.01), and the presence of shock on ICU admission had an OR of 2.24 (95% CI 1.11-4.51, P = 0.03) for the development of ARDS (Fig. 1) . Sepsis was no longer associated with ARDS development when ACLF was added into the model. Similar to the results of univariable analysis, neither alcoholic cirrhosis nor a history of alcohol use disorder was associated with ARDS development in the multivariable analysis. No collinearity occurred between any of the independent variables, and no interaction terms were found to be significant in the multivariable model. Specifically, no interactions were found between ACLF and other variables related to the components of ACLF, including sepsis, cardiovascular SOFA score ≥2, and renal SOFA score ≥2 (P > 0.05 for all). The model had good fit by the Hosmer-Lemeshow goodness-of-fit test (P = 0.18).
DISCUSSION
I N THE PRESENT study of a large cohort of critically ill patients with cirrhosis, we showed that patients with cirrhosis who develop ARDS are unique from the patients included in prior studies on ARDS. There are three important findings from the present study. First, the mortality from ARDS in patients with cirrhosis was markedly higher than previously reported in non-cirrhotic disease cohorts, 1, 2 and most cirrhotic patients who developed ARDS died in-hospital regardless of the severity of ARDS. Second, the etiology of cirrhosis and history of alcohol use disorder did not carry a significant risk for development of ARDS, in contrast to prior studies identifying alcohol use disorder as a risk factor for ARDS. 14, 28 Third, mortality did not differ significantly among the different severities of ARDS in the present study, which is contrary to the results published in prior studies that showed increasing mortality with increasing severities of ARDS. AMA, against medical advice; ARDS, of acute respiratory distress syndrome; ICU, intensive care unit; LTCH, long-term care hospital; SNF, skilled nursing facility.
Our case rate of ARDS at 8.1% was comparable with the 10.4% incidence of ARDS reported in an international multicenter epidemiological study. 2 In the fully adjusted model, sepsis was not associated with development of ARDS, but this was likely because all patients with sepsis also had an infection-related ACLF that carried the highest odds risk for ARDS development. In ARDS patients with positive cultures, the most common organisms identified in the present cohort were similar to those reported in prior literature for other cohorts of patients with ARDS. 29 However, the most common sources of positive cultures in the present cohort were slightly different from prior studies showing that the lung was the most common site of infection in ARDS patients. 30 The median time from hospital admission to ARDS development was 2.6 days, which was comparable with the time of onset of ARDS previously reported in the literature. 31, 32 However, the risk modifiers for development of ARDS in the present cohort of patients with cirrhosis were different from the findings reported in prior studies of other cohorts of patients with ARDS. For example, the proportion of alcohol use disorder was similar between ARDS and non-ARDS patients, and alcoholic cirrhosis as well as alcohol use disorder did not carry an increased odds risk for development of ARDS in our patient cohort. Prior studies examining alcohol use disorder showed an increased risk for ARDS development in patients with sepsis.
14 Similar to the present study, the authors showed in their cohort of septic shock patients that the association of chronic hepatic dysfunction was most strongly associated with mortality from ARDS. However, the authors did not examine the role of the etiology of cirrhosis in the development of ARDS. We showed that the etiology of cirrhosis was not a major determinant for ARDS development. More studies are required to investigate the interaction between alcohol use disorder and alcoholic cirrhosis in regard to the development of ARDS.
ARDS was associated with significant morbidity and mortality in the present cohort of critically ill patients with cirrhosis, resulting in lower median 28-day ICU-free days and lower median 28-day ventilator-free days compared with the patients without ARDS. Mortality was extremely high, with in-hospital death occurring in 82.2% of patients who developed ARDS, compared with just 27.6% in Figure 1 Multivariable logistic regression for risk factors and predisposing conditions for acute respiratory distress syndrome (ARDS) development. Candidate variables with P < 0.2 in the univariable analysis were examined in a multivariable logistic regression analysis. These included sepsis, male sex, diabetes, shock on admission, and renal dysfunction, all examined as dichotomous variables. Cirrhosis type as a dichotomous variable for alcoholic cirrhosis (yes or no) and Model for End-Stage Liver Disease -Sodium (MELD-Na) score (as a continuous variable) were forced into the model, because they were the primary aims of this study. Acute-on-chronic liver failure (ACLF) was also added into the model to determine its association with ARDS. Results were as follows: sepsis (OR 2.59, 95% CI 0.94-7.13, P = 0.07), male sex (OR 1.58, 95% CI 0.80-3.15, P = 0.19), diabetes (OR 1.75, 95% CI 0.87-3.54, P = 0.12), alcoholic cirrhosis (OR 1.15, 95% CI 0.56-2.36, P = 0.71), shock on intensive care unit admission (OR 2.24, 95% CI 1.11-4.51, P = 0.03), renal dysfunction (OR 0.68, 95% CI 0.31-1.51, P = 0.34), MELD-Na (OR 1.03, 95% CI 0.98-1.07, P = 0.30), and ACLF (OR 8.69, 95% CI 2.28-33.18, P < 0.01).
patients without ARDS. The mortality associated with ARDS was significantly higher than a recently published mortality rate ranging from 34.9% for mild ARDS to 46.1% for severe ARDS. 2 The mortality in the present study was more comparable with, but still higher than, a recent study showing a 62% mortality rate in patients with cirrhosis who developed ARDS. 33 Interestingly, mortality did not differ significantly among the different severities of ARDS in the present study, which is contrary to the results published in the Berlin definition 1 and other studies 2 that showed increasing mortality with increasing severities of ARDS. One contributing factor is that patients with cirrhosis tend to rapidly progress in severity of ARDS, which was the case in the large majority of the present patients. The progression in the severity of hypoxemia in ARDS and the high mortality rate appear to be unique to this phenotype, and should be further examined separately from other phenotypes of ARDS. Another consideration is that the lung protective ventilation strategy was not followed in many patients, as shown by the tidal volume-to-ideal body weight ratios that were comparable between ARDS and non-ARDS patients. However, the data presented herein do not clarify whether this occurred due to physiological or pulmonary mechanic limitations in patients with cirrhosis or due to practice behaviors.
A recent study by Gacouin et al. 33 has also explored the mortality associated with cirrhosis in patients who had ARDS according to the older American-European Consensus Conference Definition, 34 and concluded that cirrhosis was a poor prognostic factor in patients with ARDS. However, this prior study showed a similar mortality between cirrhotic patients who developed ARDS and those without ARDS. It also showed that the non-pulmonary SOFA scores were higher in cirrhotic patients than in noncirrhotic patients, whereas the pulmonary SOFA scores did not differ, suggesting that the increased mortality was related to extrapulmonary organ failures rather than hypoxemia. The present study shows several contrasting findings. First, cirrhotic patients who developed ARDS actually had markedly higher mortality than those without ARDS in the present study. Also, neither an increase in cardiovascular or renal SOFA score nor a higher severity of ARDS were associated with increased in-hospital mortality in our cohort. This suggests that the increased mortality from ARDS in patients with cirrhosis might be intrinsically related to the presence of ARDS, rather than the severity of hypoxemia or extrapulmonary organ dysfunction. Further studies will be required to reconcile these contrasting findings, and to elucidate the contribution of respiratory versus extrapulmonary organ failure for mortality in cirrhotic patients with ARDS.
There were several limitations to the present study. First, this was a retrospective observational study. Accurate evaluation of ARDS, and the data collection for predisposing conditions and risk modifiers for this cohort was limited by the diagnostic studies and recorded data for each patient. For example, we were unable to distinguish whether patients with a history of alcohol use disorder or alcoholic cirrhosis were still actively using alcohol at the time of inclusion. This could indirectly affect the development of ARDS through other causes, such as aspiration, as well as the secondary outcome of most recent transplant status. The present study was also a single-center study, which limits the generalizability of this data to cirrhotic patients in other institutions or geographic regions. The absolute number of ARDS cases identified was also relatively small, which might have resulted in insufficient power to detect important risk factors for ARDS development. Future studies will be necessary to identify the effect of early sepsis treatment and fluid management on outcomes for ARDS in this phenotype. The role of fluid management in ARDS will be particularly important in the setting of patients with cirrhosis who tend to inappropriately increase only non-central blood volume in response to fluid resuscitation with crystalloids. 35, 36 In addition, there is evidence to support the use of albumin to prevent certain complications in patients with cirrhosis, 35 highlighting that they respond differently to fluid resuscitation compared with other critically ill patients. Therefore, the optimal strategy for fluid management for ARDS, especially in cirrhotic patients with hydrostatic edema, is another area of research that might impact the high mortality shown in the present study.
Case-rates of in-hospital death from ARDS were very high in patients with cirrhosis regardless of the PaO2/FiO2 at onset, and infection-related ACLF and the presence of shock on admission were the strongest risk factors for development of ARDS in this cohort. We showed substantial differences in risk factors and outcomes in the cirrhosis phenotype from other patient phenotypes in ARDS that were previously studied. Focused and tailored interventions for prevention and early diagnosis of decompensated cirrhotic patients on the wards with infections might be an important intervention for prevention of ARDS and improvement of health outcomes.
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